| Primary | Evaluation of Disease Duration: Time From Diagnosis to Disease-Modifying Anti-Rheumatic Drug Treatment in Rheumatoid Arthritis | The time elapsed from diagnosis of rheumatoid arthritis to initiation of treatment with disease-modifying anti-rheumatic drugs (DMARDs). | All participants with available information were included in the analysis. | Posted | | Mean | Standard Deviation | Months | | Day 1 | | | | ID | Title | Description |
|---|
| OG000 | Turkish Patients With Rheumatoid Arthritis | Patients diagnosed with rheumatoid arthritis who had received at least one disease-modifying anti-rheumatic drug, who are already employed at a paid work and able to provide disease history data. |
| | | Title | Denominators | Categories |
|---|
| | |
| |
| Secondary | Work Limitation: Health Assessment Questionnaire-Disability Index (HAQ-DI) | The HAQ-DI measures physical function by assessing the ability to perform daily living tasks. Each task is rated from 0 (no difficulty) to 3 (unable to do). The total score ranges from 0 to 3. Higher scores indicate impairment. | All participants who completed the rating scales were included in the analysis. | Posted | | Mean | Standard Deviation | Units on a scale | | Day 1 | | | | ID | Title | Description |
|---|
| OG000 | Turkish Patients With Rheumatoid Arthritis | Patients diagnosed with rheumatoid arthritis who had received at least one disease-modifying anti-rheumatic drug, who are already employed at a paid work and able to provide disease history data. |
| |
| Secondary | Work Limitation: Work Productivity and Activity Impairment (WPAI) Questionnaire | The WPAI evaluates the ability to work and perform regular activities. The scale yields 4 types of scores (range 0 to 100): Absenteeism (work time missed); Presenteeism (impairment at work/reduced on-the-job effectiveness); Work Productivity Loss (overall work impairment/absenteeism plus presenteeism); and Activity Impairment. Higher scores indicate impairment. | All participants who completed the rating scales were included in the analysis. | Posted | | Mean | Standard Deviation | Units on a scale | | Day 1 | | | | ID | Title | Description |
|---|
| OG000 | Turkish Patients With Rheumatoid Arthritis | Patients diagnosed with rheumatoid arthritis who had received at least one disease-modifying anti-rheumatic drug, who are already employed at a paid work and able to provide disease history data. |
| |
| Secondary | Evaluation of Global Rheumatoid Arthritis Severity Scale | Global rheumatoid arthritis severity was assessed by asking the participants to consider all the ways their rheumatoid arthritis affected them and to rate how they were doing on a scale of 0 (very well) to 10 (very poor). | All participants with available information were included in the analysis. | Posted | | Mean | Standard Deviation | Units on a scale | | Day 1 | | | | ID | Title | Description |
|---|
| OG000 | Turkish Patients With Rheumatoid Arthritis | Patients diagnosed with rheumatoid arthritis who had received at least one disease-modifying anti-rheumatic drug, who are already employed at a paid work and able to provide disease history data. |
| |
| Secondary | Evaluation of Disease Activity Score 28 (DAS28) | The DAS28 index measures disease activity in rheumatoid arthritis and is derived from the number of swollen/tender joints, laboratory tests of inflammation, and participant assessment of global health (by marking a 100 mm line from "very good" to "very bad"). A higher score indicates worse control of disease. A DAS28 less than 3.2 indicates low disease activity and a DAS28 greater than 5.1 indicates high disease activity. | All participants with available information were included in the analysis. | Posted | | Number | | Participants | | Day 1 | | | | ID | Title | Description |
|---|
| OG000 | Turkish Patients With Rheumatoid Arthritis | Patients diagnosed with rheumatoid arthritis who had received at least one disease-modifying anti-rheumatic drug, who are already employed at a paid work and able to provide disease history data. |
| |
| Secondary | Evaluation of Visual Analog Scale (VAS) for Pain and Fatigue | Participants rated their pain and fatigue using a visual analog scale from 0 to 10, where 10 was the worst case. | Participants who provided a visual analog scale rating for pain and fatigue were included in the analysis. | Posted | | Mean | Standard Deviation | Units on a scale | | Day 1 | | | | ID | Title | Description |
|---|
| OG000 | Turkish Patients With Rheumatoid Arthritis | Patients diagnosed with rheumatoid arthritis who had received at least one disease-modifying anti-rheumatic drug, who are already employed at a paid work and able to provide disease history data. |
| |
| Secondary | Number of Disease Modifying Anti-Rheumatic Drugs | The number of disease-modifying anti-rheumatic drugs (DMARDs) that participants were taking to treat their rheumatoid arthritis. | All participants with available information were included in the analysis. | Posted | | Number | | Participants | | Day 1 | | | | ID | Title | Description |
|---|
| OG000 | Turkish Patients With Rheumatoid Arthritis | Patients diagnosed with rheumatoid arthritis who had received at least one disease-modifying anti-rheumatic drug, who are already employed at a paid work and able to provide disease history data. |
| |
| Secondary | Biologics Usage | Biologic treatments participants were taking for their rheumatoid arthritis. | All participants with available information were included in the analysis. | Posted | | Number | | Participants | | Day 1 | | | | ID | Title | Description |
|---|
| OG000 | Turkish Patients With Rheumatoid Arthritis | Patients diagnosed with rheumatoid arthritis who had received at least one disease-modifying anti-rheumatic drug, who are already employed at a paid work and able to provide disease history data. |
| | |
| Secondary | Stiffness Duration | Participants' duration of morning joint stiffness. | All participants with available information were included in the analysis. | Posted | | Number | | Participants | | Day 1 | | | | ID | Title | Description |
|---|
| OG000 | Turkish Patients With Rheumatoid Arthritis | Patients diagnosed with rheumatoid arthritis who had received at least one disease-modifying anti-rheumatic drug, who are already employed at a paid work and able to provide disease history data. |
| | |
| Secondary | Number of Comorbidities | Number of comorbid (coexisting) medical conditions of the study participants. | All participants with available information were included in the analysis. | Posted | | Number | | Participants | | Day 1 | | | | ID | Title | Description |
|---|
| OG000 | Turkish Patients With Rheumatoid Arthritis | Patients diagnosed with rheumatoid arthritis who had received at least one disease-modifying anti-rheumatic drug, who are already employed at a paid work and able to provide disease history data. |
| | |
| Secondary | Rheumatoid Factor | Rheumatoid factor test results. | All participants with available information were included in the analysis. | Posted | | Number | | Participants | | Day 1 | | | | ID | Title | Description |
|---|
| OG000 | Turkish Patients With Rheumatoid Arthritis | Patients diagnosed with rheumatoid arthritis who had received at least one disease-modifying anti-rheumatic drug, who are already employed at a paid work and able to provide disease history data. |
| | |
| Secondary | Anti-cyclic Citrullinated Peptide | Anti-cyclic citrullinated peptide (anti-CCP) test results. | All participants with available information were included in the analysis. | Posted | | Number | | Participants | | Day 1 | | | | ID | Title | Description |
|---|
| OG000 | Turkish Patients With Rheumatoid Arthritis | Patients diagnosed with rheumatoid arthritis who had received at least one disease-modifying anti-rheumatic drug, who are already employed at a paid work and able to provide disease history data. |
| | |
| Secondary | Sedimentation Rate | The erythrocyte (red blood cell) sedimentation rates of study participants were assessed. | All participants with available information were included in the analysis. | Posted | | Mean | Standard Deviation | millimeters/hour | | Day 1 | | | | ID | Title | Description |
|---|
| OG000 | Turkish Patients With Rheumatoid Arthritis | Patients diagnosed with rheumatoid arthritis who had received at least one disease-modifying anti-rheumatic drug, who are already employed at a paid work and able to provide disease history data. |
| |
| Secondary | Number of Deformities at Inspection | The number of joint deformities of the study participants. | All participants with available information were included in the analysis. | Posted | | Number | | Participants | | Day 1 | | | | ID | Title | Description |
|---|
| OG000 | Turkish Patients With Rheumatoid Arthritis | Patients diagnosed with rheumatoid arthritis who had received at least one disease-modifying anti-rheumatic drug, who are already employed at a paid work and able to provide disease history data. |
| | |
| Secondary | Evaluation of Rheumatoid Arthritis Treatments Duration | Time elapsed from onset of symptoms to diagnosis of rheumatoid arthritis (that is, from the first rheumatoid arthritis-related symptoms to diagnosis by a related specialist) and the time elapsed from diagnosis with rheumatoid arthritis to initiation of anti-tumor necrosis factor (anti-TNF) treatment. | All participants with available information were included in the analysis. | Posted | | Mean | Standard Deviation | Months | | Day 1 | | | | ID | Title | Description |
|---|
| OG000 | Turkish Patients With Rheumatoid Arthritis | Patients diagnosed with rheumatoid arthritis who had received at least one disease-modifying anti-rheumatic drug, who are already employed at a paid work and able to provide disease history data. |
| |